Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis by Evans, CE et al.
METHODS & TECHNIQUES
Modelling pulmonary microthrombosis coupled to metastasis:
distinct effects of thrombogenesis on tumorigenesis
Colin E. Evans1,2, Asis Palazon1, Jingwei Sim1, Petros A. Tyrakis1, Alice Prodger1, Xiao Lu1, Saria Chan1,
Pär-Ola Bendahl3, Mattias Belting3, Love Von Euler4, Helene Rundqvist4, Randall S. Johnson1,4,* and
Cristina Branco1,*
ABSTRACT
Thrombosis can cause localized ischemia and tissue hypoxia, and
both of these are linked to cancer metastasis. Vascular micro-
occlusion can occur as a result of arrest of circulating tumour cells
in small capillaries, giving rise to microthrombotic events that
affect flow, creating localized hypoxic regions. To better understand
the association between metastasis and thrombotic events, we
generated an experimental strategy whereby we modelled the effect
of microvascular occlusion in metastatic efficiency by using inert
microbeads to obstruct lungmicrovasculature before, during and after
intravenous tumour cell injection.We found that controlled induction of
a specific numberof thesemicrothrombotic insults in the lungs caused
an increase in expression of the hypoxia-inducible transcription
factors (HIFs), a pro-angiogenic and pro-tumorigenic environment, as
well as an increase in myeloid cell infiltration. Induction of pulmonary
microthrombosis prior to introduction of tumour cells to the lungs had
no effect on tumorigenic success, but thrombosis at the time of tumour
cell seeding increased number and size of tumours in the lung,
and this effect was strikingly more pronounced when the micro-
occlusion occurred on the day following introduction of tumour
cells. The tumorigenic effect of microbead treatment was seen even
when thrombosis was induced five days after tumour cell injection.
We also found positive correlations between thrombotic factors
and expression of HIF2α in human tumours. The model system
described here demonstrates the importance of thrombotic insult in
metastatic success and can be used to improve understanding of
thrombosis-associated tumorigenesis and its treatment.
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INTRODUCTION
There is extensive evidence that cancer is a thrombotic disease
(Blom et al., 2005; Douketis et al., 2009; Sorensen et al., 2012).
Significant levels of thrombosis accompany many cancers, notably
lung cancer, and cancer treatments such as cytotoxic chemotherapy
are themselves thrombotic (Blom et al., 2005). Since the stage of
furthest progression of most cancers is its dissemination to distant
organs, or metastases, and since the lung is one of the most common
and devastating areas for secondary tumour establishment, it is
important to understand how thrombotic events could lead to, or
even promote, metastatic success.
Thrombotic events in cancer include thrombosis and
thromboembolisms, which may be caused by a range of factors,
including tumour-induced changes in plasma coagulants,
inflammation (and the consequent activation of the endothelium
leading to increased adhesion), along with vessel obstruction,
whether by tumour-derived cell debris or circulating tumour cells
(Varki, 2007). As the pulmonary capillary bed is so extensive and
sustains such a high rate of circulatory throughput, many of these
effects are necessarily concentrated there. Thromboembolism is a
common cause of death in cancer patients, and both thrombosis and
thromboembolism are independent indicators of this condition
(Douketis et al., 2009; Sorensen et al., 2012); this association is
substantiated by evidence that that anti-coagulants protect against
pulmonary metastasis, while thrombotic agents have the opposite
effect (Belting, 2014; Langer et al., 2006; Varki, 2007; Wenzel
et al., 2010). There is, however, a lack of experimental models that
facilitate elucidation of the mechanisms by which microvascular
occlusion and thrombosis promote metastasis.
The primary aim of this study was to develop a mouse model of
thrombosis-associated metastasis in the pulmonary vasculature, and
to determine how microvascular occlusion affects pulmonary
tumour formation. We show here that pulmonary microthrombosis
enhances tumour formation, and that it does so in a manner that is
dependent on the time at which such insult is induced with respect to
the introduction of tumour cells. The model systems presented in
this study provide an experimental means of investigating
thrombosis-associated tumour spread and its potential treatment.
RESULTS
Microbead-induced pulmonary microvascular occlusion
induces acute microthrombosis
During tumorigenesis, microthrombi can arise in a number of ways,
such as from microvascular occlusion by tumour cell aggregates,
or fibrin formation as a result of tumour-increased clotting
mechanisms (Varki, 2007). To investigate the relationships between
thrombosis, hypoxic response, andmetastatic success,we developed a
method for modelling ischemic/thrombotic events, one that removed
the biological component of the event and its inherent variability. We
injected fluorescently-tagged polystyrene microbeads with a mean
diameter of 15 μm into the tail vein of adult mice. As pulmonary
capillaries in rodents have been shown to have a mean diameter of
approximately 6 μm, with a range of between 3-11 μm (Short et al.,
1996), a bead this size was expected to pass through the venousReceived 7 February 2017; Accepted 15 March 2017
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circulation and pre-capillary pulmonary circulation to cause a direct
blockage of capillary flow; this method can thus allow direct
determination of the effect of timed, coordinated ischemic events on
the fate of tumour cells in the venous circulation.
Approximately 1000 microbeads were injected intravenously, a
number that did not cause any discernible respiratory distress. The
microbeads that seeded in the pulmonary microvasculature could be
visualized by fluorescence (Fig. 1A), and ∼85% could still be
Fig. 1. Administration of intravenousmicrobeads induces pulmonarymicrothrombosis. (A) Microbeads (yellow, 15 μmdiameter) either isolated (left panel)
or seeded intravenously into the pulmonary microvasculature at day 14 post-administration. (B) Representative lung sections were stained with MSB at day 1 post
administration of intravenous microbeads or vehicle. (C) Number of total and (D) occlusive pulmonary microthrombi at various times following intravenous
administration of microbeads or vehicle. (E) Pulmonary HIF1α and HIF2α levels at various times post-administration of intravenous microbeads. N=5/group.
RBCs, red blood cells. *P<0.05 and ***P<0.001 versus vehicle-treated controls; unpaired two-tailed Student t-tests. Means±s.e.
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detected at day 14 post-administration. This was estimated by
calculating the average number of beads per cross-section and
multiplying by number of cross-sections per lung. The formation of
microthrombi as a result of microbead administration was assessed
over time (Fig. 1B); total microthrombi numbers peaked at day 1
post-microbead injection, and returned to below baseline levels after
five days (Fig. 1C). Of the microthrombi present, those that were
completely occlusive were elevated as soon as one hour after
injection, and resolved to levels not significantly above background
after two days (Fig. 1D). This shows that the administration of the
microbeads has an immediate but transient occlusive effect. We also
monitored the hypoxic response to the local ischemic events by
quantifying levels of pulmonary hypoxia-inducible factor (HIF)1α
and HIF2α (Fig. 1E). There was a dramatic increase in HIF1α levels
in the first 24 h, followed by a decrease, in a pattern that mirrors the
microthrombi resolution. The stabilization of HIF2α occurred at a
slower rate, and to comparatively lower levels than those observed
for HIF1α, but decreased at a slower rate, suggesting distinct roles
for each HIFα isoform in response to microvascular occlusion.
When pulmonary expression of both HIFα isoforms was
enhanced compared to the vehicle controls (i.e. at day 1 post-
treatment), regions of the pulmonary microvasculature that
contained microbeads stained positively for HIF1α, HIF2α, and a
macrophage cell marker, Mac2, on contiguous tissue sections
(Fig. S1A). Interestingly, HIF1α- and HIF2α-positive staining was
not confined to the sites of micro-occlusion, as we found increased
signal for these transcription factors in regions of the pulmonary
microvasculature (including lining vessel walls) that were not
immediately adjacent to microbeads (Fig. S1B), suggesting a relay
signal to surrounding tissues, potentially to circumvent or correct
local vascular obstruction.
Pulmonary microvascular occlusion increases pro-
tumorigenic environment
Given that microbead administration gave rise to increases in
pulmonary levels of HIF1α and HIF2α at day 1 post-treatment, we
investigated whether this form of micro-occlusion could also result
in enhanced local or systemic tumorigenic response. A panel of 53
tumorigenic or angiogenic factors were measured in the lungs and
circulation of microbead-treated mice and their vehicle controls.
Although microbead administration gave rise to modest increases in
the levels of 35 (66%) of these factors in whole lung homogenates at
day 1, none of these differences reached statistical significance
(Table S2), likely because the obstruction is in very small regions
and sampling thewhole organ inevitably dilutes the signal produced
at the site of occlusion. However, the levels of several tumorigenic
factors detected in the circulation at day 1 post-microbead injection
were significantly higher than those found in the circulation of
vehicle control animals. All of these factors, i.e. insulin-like growth
factor binding protein (IGFBP) 1, interleukin (IL) 1α, IL1β, and
thymidine phosphorylase [TP, formerly known as platelet-derived
endothelial cell growth factor (PD-ECGF)] (Fig. 2A-D) are,
notably, hypoxia-responsive (Giatromanolaki et al., 2003;
Nagaoka et al., 1998; Nijaguna et al., 2015; Tannahill et al.,
2013). This finding reinforces the role of systemic signals in the
response to even microvascular thrombotic insults.
Pulmonary micro-occlusion increases tumour burden in a
time-dependent fashion
To ascertain the period of time in which any pro-metastatic effect of
pulmonary microvascular occlusion on tumorigenesis could occur
(relative to tumour cell seeding), microbeads were introduced 1 or
5 days before, at the same time, or 1 or 5 days after tumour cell
injection into the tail vein. As can be seen in Fig. 3A-C, injection of
microbeads at either 1 or 5 days prior to tumour cells had no
significant effect on either the number of tumour foci or the overall
area of tumour tissue in lungs. However, tumour burden increased
significantly when the microbeads were co-injected with tumour
cells, and the maximal tumorigenic effect, both on tumour size and
number, was observed when microbeads were injected the day
following the tumour cells. When the microbeads were introduced
5 days after the tumour cells, there were smaller but still significant
increases in tumour number and size.
To investigate if the tumours were developing at the sites where
microbeads had been arrested, we compared the number of
microbeads within lung tumours between experimental groups at
end-point (i.e. day 14 post-LLCs). Interestingly, we found that there
were more microbeads in the tumours of mice receiving beads the
day after tumour cells, when compared with those receiving beads
before or concomitantly with the tumour cells (Fig. 3D), while
microthrombi size (Fig. 3E), erythrocyte content (Fig. S2A), and
collagen content remained similar across all treatments (Fig. S2B).
Microbead-induced increases in tumour formation (i.e. those
observed when beads were given after LLC injection) were
accompanied by concomitant increases in both pulmonary HIF1α
and pulmonary HIF2α expression (Fig. 4A,B). In these mice, strong
staining for HIF1α and HIF2α was observed in regions of
pulmonary tumour that also stained strongly for Mac2 (Fig. 4B).
To determine whether the greatest increases in tumour burden
could be driven by increases in circulating tumorigenic factors, the
same panel of 53 tumorigenic factors described above were
measured in the circulation of tumour-bearing microbead- and
Fig. 2. Tumorigenic factors are increased in the circulation of microbead-
treatedmice. (A-D) Quantification of tumorigenic factors IGFBP1 (A), IL1α (B),
IL1β (C), and TP (D) in the circulation of mice at day 1 post-administration of
intravenous vehicle or microbeads. Abbreviations are provided in Table S2.
N=5/group. *P<0.05 and **P<0.01; unpaired two-tailed Student t-tests.
Means±s.e.
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vehicle-treated mice on day 14 post-LLCs (endpoint). In microbead-
treated mice versus vehicle controls, there were increases in the
circulating levels of delta-like ligand protein (DLL) 4, fibroblast
growth factor (FGF) 7, fractalkine, IGFBP10, IL10, and TP
(Fig. 5A-F), all of which are involved in either angiogenesis or
inflammation, processes that are essential for successful tumour
establishment.
Diverse pulmonary thrombotic insults increase tumour
burden in a time-dependent fashion
During the optimization stages of this study, we also examined the
effect of two other thrombotic agents on tumorigenesis. First, we
substituted the microbeads with approximately 1000 fibrin
microthrombi per mouse. These fibrin fragments were generated
from fibrinogen activated in vitro and also had an approximate
diameter of 15 µm (Lam et al., 2010). They also arrested in the
pulmonary microvasculature and remained intact at day 14 post-
administration (Fig. S3A). There were no significant effects of this
form of micro-occlusion on tumorigenesis when the fibrin
microthrombi injections occurred one day prior to, or at the same
time as, administration of the tumour cells. However, and similarly
to what was shown in the microbeads model, introduction of fibrin
microthrombi 1 day after the tumour cells more than doubled the
number of tumour foci detectable in the lungs, and this was
accompanied by an overall doubling in the area of the lung filled by
tumour mass (Fig. S3B,C).
Second, we evaluated the effect of introducing non-viable (heat-
killed) tumour cells in place of the microbeads. In this case, the pro-
tumorigenic impact occurred exclusively when dead and live tumour
cells were injected simultaneously (Fig. S3D,E). These qualitative
differences indicate that, although different types of thrombotic
insults can enhance tumour formation in the lung, the nature of the
agents can directly impact outcome; these discrepancies are likely in
part due to the expected variability in populations of dead cells and
fibrin fragments, including differential persistence in the vasculature
and differential inflammatory potential.
Fig. 3. Microbead-induced pulmonary
microthrombosis increases tumour
formation in a temporal manner.
(A) Representative lung sections stained
with H&E following intravenous injection
of vehicle or microbeads given 1 day
prior (−1), at the same time (0), or 1 day
after (+1) intravenous LLCs. (B) Number
and (C) area of pulmonary tumours
following intravenous microbead
administration at different times with
respect to intravenous injection of LLCs.
(D) Number of tumour microbeads, and
(E) microthrombi size. Mice were culled
at day 14 post-LLCs. N=5/group.
*P<0.05, ***P<0.001, and ****P<0.0001
versus vehicle-treated controls; #P<0.05
versus days −5, −1, and 0; *, ***, and
****: unpaired two-tailed Student t-tests.
#: ANOVA with Bonferroni post-test.
Means±s.e.
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Correlations between thrombotic markers and HIFα in
cancer patients
To determine whether thrombosis could trigger a HIF-mediated
tumorigenic response in cancer patients, human breast and
pancreatic tumour samples were analysed. In breast tumours,
activated levels of the initiator of the coagulation cascade,
phosphorylated tissue factor, were shown to be positively
correlated with HIF1α expression in a recent study (Evans et al.,
2016). In this study, we found that expression of phosphorylated
tissue factor was also positively correlated with HIF2α expression
(RS=0.2; P<0.005, Fig. 6A). Furthermore, we showed herein that
tumour levels of the thrombotic marker plasminogen activator
inhibitor 1 (PAI1), and tumour levels of the tissue factor signalling
receptor protease activated receptor 2 (PAR2), were positively
correlated with HIF2α but not HIF1α levels (Table 1). Finally,
levels of fibrin (the terminal protein of the coagulation cascade)
were also positively correlated with HIF2α (but not HIF1α)
expression in breast (RS=0.22; P<0.001, Fig. 6B) and pancreatic
tumours (RS=0.33; P<0.01, Fig. 6C).
DISCUSSION
Hypercoagulation is often associated with exacerbated pulmonary
metastasis, and it has been suggested that microthrombosis could
promote metastasis by providing a scaffold for cancer cell
attachment and trans-endothelial migration, a binding site for pro-
metastatic growth factors and cytokines, or protection of cancer cells
from natural killer cell-mediated elimination (Palumbo et al., 2005,
2007; Varki, 2007). Here we present three novel models of
thrombotic occlusion coupled with metastasis in the pulmonary
microvasculature, and demonstrate that these distinct insults
Fig. 4. Microbead-induced
increases in pulmonary tumour
formation are associated with
increases in HIF1α and HIF2α
expression and macrophage
infiltration. (A) Pulmonary HIF1α and
HIF2α levels following microbead-
induced pulmonary thrombosis in
mice receiving intravenous
microbeads at different times with
respect to the administration of
intravenous LLCs. (B) Representative
lung sections stained for HIF1α,
HIF2α, and myeloid cell Mac2 (dark
grey/black) following intravenous
administration of LLCs and either
vehicle or microbeads at 1 day post-
LLCs. Mice were culled at day 14
post-LLCs. N=5/group. *P<0.05 and
**P<0.01 versus vehicle-treated
controls; unpaired two-tailed Student
t-tests. Means±s.e.
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enhance pulmonary tumour formation in a time-dependent manner.
We also show that these effects depend on the nature of the
obstruction.
In the current study, we present a model whereby capillary
blockade by administration of sterile and inert microbeads results in
the formation of obstructing and occlusive microthrombi in the lung
microvasculature. These events lead to distinct temporal patterns in
the activation of HIF1α and HIF2α in lungs, as well as increased
infiltration of myeloid cells, chronological patterns that are
comparable with those found following induction of occlusive
thrombosis in an established vena cava rodent model (Evans et al.,
2010, 2014c). Our findings are also consistent with observations
that expression of the two major HIFα isoforms is distinct and
dependent on cellular, tissue and pathological context (Elson et al.,
2000; Mowat et al., 2010; Yu et al., 1998). Following thrombus
formation, HIF1 activation and increased expression of proteolytic/
fibrinolytic factors stimulate thrombus resolution (Evans et al.,
2010), which could contribute to the reduction in microthrombi
formation seen at 5 days after the introduction of occlusive
microbeads to the pulmonary capillaries. Experimental studies of
human pulmonary diseases modelled in murine lung could improve
understanding of the mechanisms that control the distinct temporal
expression patterns of the HIFα isoforms following vascular
occlusion.
The finding that pulmonary tumour burden is only increased
when microbead-induced pulmonary microthrombosis is given at
the same time or after the introduction of circulating tumour cells is
intriguing and requires further characterization in mechanistic
studies. On one hand, it is possible that this effect is partly
dependent upon a biomechanical influence of microvascular
occlusion (Guo et al., 2014). In other words, tumour cells that
arrest in the pulmonary microvasculature may be ‘pushed’ into the
extra-vascular tissue by these micro-occlusive insults. This
possibility is supported by the presence of microbeads at or
outside of the pulmonary tumour periphery, and the attenuated
effect of administering fibrin microthrombi, which are more
malleable than microbeads, on pulmonary tumorigenesis.
However, the fact that microbead administration results in
significant increases in systemic levels of angiogenic,
inflammatory and tumorigenic factors also suggests that these
local ischemic insults are able to induce a response that is either
secreted or diffusive. To verify whether circulating tumour cells
preferentially arrest and extravasate at the site of microbead
occlusion, intra-vital imaging of in vivo or ex vivo explanted lungs
could be performed in future studies using different tumour cell
lines (Mendoza et al., 2010).
The milder pro-metastatic effect elicited by fibrin microthrombi
compared with microbeads is not unexpected, given that fibrin
microthrombi may also be lysed, and can more easily be removed or
extravasated from the circulation (Lam et al., 2010). Intra-venous
polystyrene microbeads, however, whose number and size can be
more accurately controlled, provide a relevant means of studying the
effect of local vascular occlusion on the metastatic process in a
model system where the occluding agent is not subject to
phagocytosis or biological degradation, as may be the case with
fibrin microthrombi and non-viable tumour cells. Non-viable
tumour cells are also more likely to form aggregates, as well as
stimulate additional and more intricate physiological responses, and
the effect of circulating tumour cells (viable or not) will create an
environment considerably more complex than capillary obstruction
Fig. 5. Tumorigenic factors are
increased by microbead treatment in
the circulation of tumour-bearing
mice. (A-F) Quantification of DLL4 (A),
FGF7 (B), fractalkine (C), IGFBP10 (D),
IL10 (E), and TP (F) in the circulation of
vehicle- and microbead-treated mice at
day 14 post-LLC injection. Mice
received intravenous microbeads at day
1 post-intravenous LLCs. Abbreviations
are provided in Table S2. N=4-5/group.
*P<0.05, **P<0.01, and ****P<0.0001;
unpaired two-tailed Student t-tests.
Means±s.e.
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alone. For that reason, to study the effect of vascular micro-
occlusion in isolation, we chose to optimise this model with an
inert agent.
We show here that the systemic expression of multiple pro-
tumorigenic factors is increased following microbead-induced
microthrombi formation in the pulmonary microvasculature. All
of these factors are hypoxia responsive and were seen to be elevated
from as early as 1 day post-microbeads until as late as 14 days post-
LLCs, although the distinct temporal expression patterns of
individual tumorigenic factors were not fully characterized in this
study. HIF target genes include many factors that exert strong pro-
metastatic effects (Cramer et al., 2003; Imtiyaz and Simon, 2010).
Given that pulmonary microthrombosis leads to upregulation of
both HIF1α and HIF2α levels, we speculate that stabilization of
these factors promotes tumorigenesis through increased secretion of
pro-tumorigenic growth factors, as well as pro-inflammatory
cytokines, a finding corroborated by the associated infiltration of
Mac2-positive cells. This possibility is also supported by previous
demonstrations that HIF1α and HIF2α are induced in occlusive and
propagating venous thrombus, respectively, and are also expressed
in the vessel wall adjacent to occlusive and propagating venous
thrombus. Also, pharmacological upregulation of HIF1α in
Fig. 6. Positive correlations between
thrombotic factors andHIF2α expression in
human breast and pancreatic tumours.
(A) Immunostaining for HIF2α (black) and
phosphorylated tissue factor (pTF, brown) in
human breast tumour microarrays.
(B) Correlation between levels of HIF2α and
fibrin in human breast tumours (RS=0.22;
P<0.001) and (C) human pancreatic tumours
(RS=0.33; P<0.01).
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thrombosed mice increases the local expression of numerous pro-
metastatic HIF targets, whereas inhibition of HIF1α accumulation
supresses this local pro-metastatic drive (Evans et al., 2010, 2011,
2012, 2014a,b).
Although the relative contributions of cell-specific HIFs to
thrombosis-associated tumorigenesis were not examined in this
study, conditional tissue-specific mutant models are ideal tools
for subsequent studies of such mechanisms that regulate
microthrombosis-induced tumour dissemination and establishment.
Future studies could investigate, for example, whether microbead-
induced increases in tumour-promoting factors arise from
cells within the blood, lung parenchyma, or pulmonary tumour,
and whether microbead treatment gives rise to alterations in
endothelial barrier permeability. The functional contribution of
microthrombosis to metastatic progression could be assessed using
this model in combination with approved or novel anti-coagulant
pharmacotherapies.
Strong correlations between thrombotic markers and the two
major HIFα isoforms have been found in cohorts of breast and
pancreatic cancer patients in this and previous studies (Evans et al.,
2016). These findings support the possibility that thrombotic insults
could lead to increases in HIFα expression in humans (Hu et al.,
2003; Zerrouqi et al., 2014). Given that primary tumours commonly
metastasise to the lung, and that levels of these thrombotic markers
(along with levels of HIF1α and HIF2α) accurately predict distant
metastasis-free survival, we propose that thrombosis-induced
increases in HIF1 and HIF2 activation could also promote
metastasis in cancer patients (Bos et al., 2001, 2003; Bouchet
et al., 1994; Foekens et al., 1994; Grøndahl-Hansen et al., 1993,
1997; Helczynska et al., 2008; Janicke et al., 1993; Malmstrom
et al., 2001). Additional large-scale human studies of multiple
cancer types are required to verify the role(s) of HIFs in thrombosis-
induced tumour progression.
In summary, our novel experimental models of pulmonary
microvascular occlusion demonstrate that thrombotic insults give
rise to temporal increases in HIFα expression and tumour formation.
Further studies of the mechanisms that regulate thrombosis-induced
cancer progression could impact upon current treatment strategies
for metastatic disease.
MATERIALS AND METHODS
Cell culture and mice
Lewis lung cancer (LLC) cells were cultured in Dulbecco’s modified eagle
medium with 10% fetal bovine serum and 1% penicillin/streptavidin (Life
Technologies, UK) at 21% oxygen and 37°C. Studies were performed on
C57BL/6J mice (8-10 week-old males, Charles River, UK) under the
Animals (Scientific Procedures) Act, 1986.
Induction of microthrombosis
For studies on the induction of pulmonary microthrombosis (n=5/group),
fluorescent polystyrene microbeads were injected via the tail vein (15 μm
diameter, 1000 beads/mouse in 100 μl saline, F8842, Life Technologies,
UK). For studies on pulmonary tumour formation (n=5/group), polystyrene
microbeads (1000/mouse in 100 μl saline), or saline vehicle (100 μl) were
injected via the tail vein 1 or 5 day(s) before, at the same time, and 1 or 5 day(s)
after tail vein injection of viable LLCs (1 million/mouse in 100 μl saline).
During optimization stages of the protocol, fibrin microthrombi (15 μm
diameter, 1000/mouse in 100 µl saline) or heat-killed tumour cells (100,000/
mouse) were used as obstructive agents instead of polystyrene microbeads.
Fibrin microthrombi were generated and fluorescently labelled with Texas
Red (Invitrogen, UK) as described (Lam et al., 2010) and non-viable LLCs
were obtained by heat killing at 60°C for 30 min.
Histology and immunostaining
Mice were culled at indicated time points post-microbeads’ administration
or 14 days post-LLC injection as described (Branco-Price et al., 2012).
Lungs were fixed in 4% paraformaldehyde and embedded in paraffin and
cross-sections (7 μm) were cut at 200 μm intervals throughout the lung.
Contiguous sections were stained with haematoxylin and eosin (H&E,
Sigma Aldrich, UK), Martius Scarlet Blue (MSB, Sigma Aldrich, UK), and
for HIF1α (Novus Biologicals, UK), HIF2α (Novus Biologicals, UK), and
Mac2 (BioLegend Ltd, UK) as previously described (Evans et al., 2010,
2014a,b,c; Saha et al., 2013).
Image capture and analysis
Images were captured in a blinded fashion using a light or confocal
microscope and mounted camera (Leica, UK). Microthrombi numbers were
assessed by counting fibrin-positive (red) deposits in the microvascular
lumen of MSB-stained lung tissue as described (Evans et al., 2016).
Occlusive microthrombi were defined as those that completely filled the
vessel lumen. Fibrin, collagen, and erythrocyte content, and primary
antibody binding (for HIF1α, HIF2α, and Mac2) were assessed by
quantification of positive staining using Image J (NIH, USA) as described
(Evans et al., 2010, 2014a; Saha et al., 2013). Regions of positive staining
were delineated and expressed as a percentage of tissue cross-sectional area.
The assessment of fibrin deposition by quantification of the red regions of
MSB-stained tissue has been previously validated in an established murine
thrombosis model; i.e. fibrin levels assessed by quantification of MSB-
stained tissue correlate strongly with fibrin levels derived by both fibrin
immunostaining and western blotting (Saha et al., 2013). Tumour burden
was assessed as described (Branco-Price et al., 2012). Number of
microbeads in contact with tumour foci were counted and expressed per
surface area of tumour tissue by delineation of the tumour boundary using
Image J (NIH, USA). For all variables, an average was taken from three or
more whole lung cross-sections taken at 200 µm intervals throughout the
entire tissue.
Protein arrays
A panel of 53 tumorigenic growth factors and cytokines were measured in
the circulation and lungs of vehicle- and microbead-treated mice at day 1
post-microbeads (n=5/group) and in the circulation of tumour-bearing mice
at day 14 post-LLCs (n=4-5/group) by protein array according to
manufacturers’ instructions (Proteome Profiler Array, ARY015, R&D
Systems, UK). Serum and lung samples were also prepared according to the
manufacturers’ instructions of the array.
Human tumour microarrays
Human studies were approved by the ethics committee of Lund University
Hospital and were performed with informed consent from all subjects.
Breast tumour microarray samples and plasma were obtained from a lymph
node-negative population of breast cancer patients that have previously been
described (n=221) (Malmstrom et al., 2001). Pancreatic tumour microarray
samples were obtained from the Human Tissue Bank at NIHR Cambridge
Biomedical Research Centre (n=63, Table S1). In breast tumours, levels of
protease-activated receptor 1 and 2 were quantified by immunostaining and
image analysis as described (Ryden et al., 2010), and plasminogen activator
inhibitor 1 was quantified by enzyme-linked immunosorbent assay (ELISA)
as described (Linderholm et al., 2008;Malmstrom et al., 2001). In breast and
pancreatic tumours, fibrin content, and HIF1α and HIF2α expression were
assessed by image analysis of stained tissue as described above.
Table 1. Correlations between thrombotic factors and HIFα expression
in human breast tumours
HIF1α HIF2α
Factor RS P RS P
PAI1 −0.05 0.47 0.24 0.001
PAR1 −0.06 0.37 −0.07 0.35
PAR2 0.004 0.96 0.18 0.01
PAI, plasminogen activator inhibitor; PAR, protease-activated receptor; RS,
Spearman’s correlation. N=221.
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Statistical analysis
Pairwise comparisons were analyzed by the unpaired two-tailed Student
t-test. ANOVA with Bonferroni post-test was used to test differences
between multiple groups. Correlations were assessed using Spearman’s
correlation. Significance was assumed at P<0.05 in all analyses (Prism 5,
Graphpad, USA). Data are expressed as means±standard error.
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